Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors

Clinical and Vaccine Immunology

Volumn 21, Issue 6, 2014, Pages 901-903

  Nébié, Issa ^a   Edwards, Nick J ^b   Tiono, Alfred B ^a   Ewer, Katie J ^b   Sanou, Guillaume S ^a   Soulama, Issiaka ^a   Sanon, Souleymane ^a   Diarra, Amidou ^a   Yaro, Jean Baptiste ^a   Kangoye, David ^a   Imoukhuede, Egeruan B ^c   Hill, Adrian V S ^b   Sirima, Sodiomon B ^a  

^a Burkina Faso   (Burkina Faso)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c European Vaccine Initiative   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; MALARIA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENOVIRUS; ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CHIMPANZEE ADENOVIRUS SEROTYPE 63; COHORT ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MALARIA; PRIORITY JOURNAL; SEROTYPE; TRANSGENE; VACCINATION; VIRUS NEUTRALIZATION; ADOLESCENT; ANIMAL; BLOOD; BURKINA FASO; CLASSIFICATION; IMMUNOLOGY; INFANT; MALARIA, FALCIPARUM; MIDDLE AGED; PAN TROGLODYTES; PRESCHOOL CHILD; SIMIAN VIRUS; YOUNG ADULT;

ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BURKINA FASO; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MIDDLE AGED; PAN TROGLODYTES; YOUNG ADULT;

EID: 84901633565     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00723-13     Document Type: Article

References (19)

1. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV. 2012. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205:772-781. http://dx.doi.org/10.1093/infdis/jir850.
2. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ. 2011. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19:2269-2276. http://dx.doi.org/10.1038/mt.2011.176.
3. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. 2012. Novel adenovirus-based vaccines induce broad and sustained T cell responses toHCVin man. Sci. Transl. Med. 4:115ra111. http://dx.doi.org/10.1126/scitranslmed. 3003155.
4. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH. 2006. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 44:3781-3783. http://dx.doi.org/10.1128/JCM.01249- 06. (Pubitemid 46768807)
5. Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ. 2006. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol. 87:2891-2899. http://dx.doi.org/10.1099/vir.0.82079-0. (Pubitemid 44463897)
6. Roy S, Zhi Y, Kobinger GP, Figueredo J, Calcedo R, Miller JR, Feldmann H, Wilson JM. 2006. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J. Gen. Virol. 87:2477-2485. http://dx.doi.org/10.1099/vir.0. 81989-0.
7. Mittereder N, March KL, Trapnell BC. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509. (Pubitemid 26339054)
8. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, Patel DK, Dell EC, Franlin LL, Dougherty NM, Bennett PS, Perry HC, Davies ME, Shiver JW, Keller PM, Yeager MD. 2004. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther. 15:293-304. http://dx.doi.org/10.1089/104303404322886147. (Pubitemid 38365918)
9. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, Mwacharo J, Kai O, Nicosia A, Hill AV. 2009. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27:3501-3504. http://dx.doi.org/10. 1016/j.vaccine.2009.03.080.
10. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. 2012. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7:e40385. http://dx.doi.org/10.1371/journal.pone. 0040385.
11. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV. 2013. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4:2836. http://dx.doi.org/10.1038/ ncomms3836.
12. Wohlfart C. 1988. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62:2321-2328.
13. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. 2003. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 77:10366-10375. http://dx.doi.org/10.1128/ JVI.77.19.10366-10375.2003. (Pubitemid 37129680)
14. Farina S, Tinazzi M, Le Pera D, Valeriani M. 2003. Pain-related modulation of the human motor cortex. Neurol. Res. 25:130-142. http://dx.doi.org/10.1179/016164103101201283. (Pubitemid 36259313)
15. Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, Gao GP, Wilson JM, Ertl HC. 2006. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 13:421-429. http://dx.doi.org/10.1038/sj.gt.3302675.
16. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. 2012. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4:115ra112. http://dx.doi.org/10. 1126/scitranslmed.3002925.
17. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. 2008. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38:732-741. http://dx.doi.org/10.1002/eji.200737672.
18. + T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171:6774-6779. http://dx.doi.org/10.4049/jimmunol.171.12.6774.
19. Ersching J, Hernandez MI, Cezarotto FS, Ferreira JD, Martins AB, Switzer WM, Xiang Z, Ertl HC, Zanetti CR, Pinto AR. 2010. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407:1-6. http://dx.doi.org/10.1016/j.virol.2010.07.043.